Survodutide vs Tirzepatide
Survodutide: Dual GLP-1 / glucagon receptor agonist. Tirzepatide: Dual GIP / GLP-1 receptor agonist. Per milligram, Tirzepatide is cheaper right now (USD 1.70 vs USD 0.230 at the cheapest tested vendor). Prices per mg compare cost, not effect: the amounts used in studies differ between compounds.
Survodutide
Studied for weight loss and for fatty liver disease (MASH), where glucagon activity may help reduce liver fat.
- What it is
- Dual GLP-1 / glucagon receptor agonist
- Category
- GLP-1 & metabolic
- Status
- Investigational (Boehringer Ingelheim, Phase 3). Not approved.
- Cheapest
- USD 1.70 per mg (BeiBangAn)
- Median price
- USD 4.09 per mg
- Vendors
- 24 independently tested, 1 with a lab report
- Research
- Grade A: Strong human evidence (10 papers)
- Studied as
- studied in people
- Reported side effects
- Gastrointestinal events (nausea, diarrhea, vomiting), dose-related; Drug-related adverse events in people with cirrhosis; Serious adverse events (similar to placebo)
Tirzepatide
Activates both the GIP and GLP-1 incretin receptors, lowering blood sugar and appetite. In trials it produced more weight loss on average than GLP-1-only drugs.
- What it is
- Dual GIP / GLP-1 receptor agonist
- Category
- GLP-1 & metabolic
- Status
- FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management, obstructive sleep apnea).
- Cheapest
- USD 0.230 per mg (BeiBangAn)
- Median price
- USD 2.00 per mg
- Vendors
- 81 independently tested, 43 with a lab report
- Research
- Grade A: Strong human evidence (8 papers)
- Studied as
- an approved drug
- Reported side effects
- Nausea, diarrhea, vomiting and other GI events (mostly mild-moderate, during dose escalation); Discontinuation due to adverse events; Serious adverse events; Hypoglycemia (in type 2 diabetes)
Cheapest tested vendors for Survodutide and Tirzepatide
Lowest price per milligram at up to three independently tested vendors each. Rankings are by price only; open a vendor to see its lab results.
| Peptide | Vendor | Per mg |
|---|---|---|
| Survodutide | BeiBangAn | USD 1.70 |
| LN Peptides | USD 1.70 | |
| Bulk Peptide Wholesale | USD 2.25 | |
| Tirzepatide | BeiBangAn | USD 0.230 |
| LN Peptides | USD 0.230 | |
| Mix Peptides | USD 0.275 |
Questions people ask
What is the difference between Survodutide and Tirzepatide?
Survodutide: Dual GLP-1 / glucagon receptor agonist. Tirzepatide: Dual GIP / GLP-1 receptor agonist. Per milligram, Tirzepatide is cheaper right now (USD 1.70 vs USD 0.230 at the cheapest tested vendor). Prices per mg compare cost, not effect: the amounts used in studies differ between compounds.
Which is cheaper, Survodutide or Tirzepatide?
Tirzepatide is cheaper per mg: USD 1.70 for Survodutide vs USD 0.230 for Tirzepatide at the cheapest independently tested vendor. The median listing is USD 4.09 per mg for Survodutide and USD 2.00 per mg for Tirzepatide.
Which is easier to find from a tested vendor, Survodutide or Tirzepatide?
Tirzepatide is sold by more independently tested vendors: 24 list Survodutide (1 publish a lab report for it) and 81 list Tirzepatide (43 with a lab report).
Which has more published research, Survodutide or Tirzepatide?
Survodutide is graded A (strong human evidence) from 10 papers and Tirzepatide is graded A (strong human evidence) from 8 papers. Grades count studies of the exact compound only; they describe how much evidence exists, not which one is better.
Are Survodutide and Tirzepatide FDA approved?
Survodutide: Investigational (Boehringer Ingelheim, Phase 3). Not approved. Tirzepatide: FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management, obstructive sleep apnea).